Department of Neurology, Stanford University School of Medicine.
Stanford Neuro-Immuno-Oncology (NIO) Program, Stanford, California, USA.
Curr Opin Neurol. 2024 Dec 1;37(6):672-681. doi: 10.1097/WCO.0000000000001318. Epub 2024 Oct 9.
To review the landscape of chimeric antigen receptor T-cell (CAR T) therapy for gliomas as seen in recently published trials and discuss on-going challenges with new cancer immunotherapy treatments.
Given how CAR T therapy has revolutionized the treatment of several hematologic malignancies, there has been increasing interest in using immunotherapy, and particularly CAR T therapy for gliomas. Within the past decade, several first in human trials have published early patient experiences showing treatment is generally well tolerated but with limited efficacy, which may be improving with newer evolutions in CAR T design to overcome known resistance mechanisms in glioma treatment.
CAR T therapy is a promising avenue of treatment for high-grade gliomas, which have a universally poor prognosis as well as limited therapeutics. There are a growing number of CAR T clinical trials for CNS tumors and thus, an understanding of their treatment strategies, toxicity management, and overcoming resistance mechanisms will be important for both clinical practice and to identify areas for future research.
综述最近发表的临床试验中嵌合抗原受体 T 细胞（CAR T）疗法在治疗脑胶质瘤方面的研究进展，并讨论新的癌症免疫疗法治疗所面临的挑战。
鉴于 CAR T 疗法已彻底改变了几种血液系统恶性肿瘤的治疗方法，人们对免疫疗法，尤其是 CAR T 疗法治疗脑胶质瘤的兴趣日益浓厚。在过去十年中，几项首次人体试验发表了早期患者的经验，表明该治疗通常具有良好的耐受性，但疗效有限，随着 CAR T 设计的最新进展，可能会改善治疗脑胶质瘤的已知耐药机制。
CAR T 疗法是治疗高级别脑胶质瘤的一种很有前途的方法，高级别脑胶质瘤的预后普遍较差，且治疗方法有限。目前针对中枢神经系统肿瘤的 CAR T 临床试验越来越多，因此，了解其治疗策略、毒性管理和克服耐药机制对于临床实践以及确定未来研究领域都非常重要。
